Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial-Reference-Cited by-同舟云学术

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial

Published:2014-09 Issue:1 Volume:176 Page:55-61
ISSN:0167-5273
Container-title:International Journal of Cardiology
language:en
Short-container-title:International Journal of Cardiology

Author:

Roth Eli M.,Taskinen Marja-Riitta,Ginsberg Henry N.,Kastelein John J.P.,Colhoun Helen M.^ORCID,Robinson Jennifer G.,Merlet Laurence,Pordy Robert^ORCID,Baccara-Dinet Marie T.

Funder

Sanofi

Regeneron

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference23 articles.

1. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy;McKenney;J Am Coll Cardiol,2012

2. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia;Roth;N Engl J Med,2012

3. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

4. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol;Stein;N Engl J Med,2012

5. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project;Conroy;Eur Heart J,2003

Cited by 240 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of ongericimab given by prefilled syringe or autoinjector in primary hypercholesterolemia and mixed hyperlipidemia;Nutrition, Metabolism and Cardiovascular Diseases;2024-09

2. Efficacy and Safety of Bempedoic Acid in Patients with High Cardiovascular Risk: An Update;Current Vascular Pharmacology;2024-07

3. Towards Optimal Cardiovascular Health: A Comprehensive Review of Preventive Strategies;Cureus;2024-05-22

4. Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation;European Heart Journal - Cardiovascular Pharmacotherapy;2024-04-20

5. A bibliometric analysis of PCSK9 inhibitors from 2007 to 2022;Frontiers in Endocrinology;2023-11-29